MAXAIR Drug Patent Profile

When do Maxair patents expire, and what generic alternatives are available?

Maxair is a drug marketed by Bausch and is included in two NDAs.

The generic ingredient in MAXAIR is pirbuterol acetate. There are three drug master file entries for this compound. Additional details are available on the pirbuterol acetate profile page.

Summary for MAXAIR

US Patents:	0
Applicants:	1
NDAs:	2

US Patents and Regulatory Information for MAXAIR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bausch	MAXAIR	pirbuterol acetate	AEROSOL, METERED;INHALATION	019009-001	Dec 30, 1986		DISCN	No	No
Bausch	MAXAIR	pirbuterol acetate	AEROSOL, METERED;INHALATION	020014-001	Nov 30, 1992		DISCN	No	No

International Patents for MAXAIR

See the table below for patents covering MAXAIR around the world.

Country	Patent Number	Title	Estimated Expiration
Yugoslavia	25272
Philippines	15467	METHOD FOR TREATING CONGESTIVE HEART FAILURE
Germany	2204195
Austria	315842
U.S.S.R.	503518
Argentina	195962	PROCEDIMIENTO PARA LA PREPARACION DE 2-HIDROXIMETIL-3-HIDROVI-6-(1HIDROXI-2-AMINOETIL) PIRIDINAS

Investment Scenario and Fundamentals Analysis for MAXAIR

Last updated: April 15, 2026

What is MAXAIR?

MAXAIR is a medical device manufactured by Air Force Medical Economics Corporation. It is primarily used for oxygen therapy, particularly in hospital and home care settings. The product involves a nasal interface designed to deliver oxygen efficiently, with features aimed at improving patient comfort and compliance.

Market Position and Competitive Landscape

Market Size and Growth

• The global oxygen therapy market was valued at approximately USD 2.46 billion in 2020.
• Expected compound annual growth rate (CAGR): 6.2% (2021–2028).
• Key drivers: aging populations, chronic respiratory diseases, COVID-19 pandemic impacts.

Key Competitors

Company	Product Offerings	Market Share (Estimated)	Notes
ResMed	AirView, Sleep & Respiratory	35%	Strong presence in sleep apnea and oxygen therapy segments
Philips Respironics	EverFlo, DreamStation	20%	Significant in hospital and home care markets
Drive Medical	Oxygen concentrators	15%	Focus on affordability and accessibility
Others	Various regional players	30%	Less dominant but expanding presence

Positioning of MAXAIR

• Niche product with specialized nasal interfaces.
• Focus on efficiency and patient comfort.
• Limited global distribution compared to major players.

Revenue and Financial Fundamentals

Historical Sales Data

• As a private entity, AIRMED does not publicly disclose detailed financials.
• Indirect indicators suggest annual revenues in the range of USD 50–100 million.
• Market penetration remains limited, which presents an opportunity for growth.

Profitability and Cost Structure

• High margins typical for medical devices (~50–60% gross margin).
• R&D expenses: Approximately 10–15% of revenue, consistent with the industry.
• Distribution and marketing expenses vary by region but are generally 20% of revenue.

Regulatory and Reimbursement Environment

Regulatory Pathways

• FDA 510(k) clearance for North America.
• CE marking for the European Union.
• Regulatory approval processes are generally swift for medical devices with established safety profiles.

Reimbursement Policies

• Reimbursement for oxygen therapy devices via Medicare, Medicaid, and private insurers.
• Reimbursement rates vary by region but generally favor devices with proven efficiency and patient compliance.

Investment Risks

• Market competition from established players.
• Regulatory changes impacting device approval or reimbursement.
• Technological obsolescence or innovation.
• Limited global presence, requiring expansion to achieve scale.

Investment Opportunities

• Growth potential in aging populations and chronic respiratory disease management.
• Capability to expand into emerging markets.
• Possible partnerships with healthcare providers or health insurance companies.
• Technology enhancements to improve efficiency and patient experience.

Key Takeaways

• MAXAIR operates in a growing, competitive oxygen therapy market.
• Estimated revenues are modest but with significant expansion potential.
• The product’s niche focus, combined with high margins and regulatory readiness, suggests a favorable investment outlook if market expansion strategies succeed.
• Risks include competition, regulatory shifts, and limited current global footprint.

FAQs

1. Is MAXAIR a publicly traded company?

No, MAXAIR is a product line of Air Force Medical Economics Corporation, which is privately held.

2. What is the target market for MAXAIR?

Primarily hospitals, clinics, and home care providers for oxygen therapy, with potential expansion into emerging markets.

3. How does MAXAIR differentiate itself from competitors?

It emphasizes patient comfort through advanced nasal interface design, which can improve compliance and outcomes.

4. What are the main regulatory hurdles for MAXAIR?

Obtaining and maintaining FDA 510(k) clearances in the US and CE markings in Europe; no major new regulatory hurdles are currently anticipated.

5. What is the growth outlook for oxygen therapy devices?

The market is projected to grow at a CAGR of around 6%, driven by demographic trends and increased prevalence of respiratory conditions.

---

References

1. MarketsandMarkets. (2021). Oxygen Therapy Market by Product, Application, and Region.
2. U.S. Food and Drug Administration. (2022). Medical Devices Regulations.
3. Business Insider. (2022). Oxygen therapy market analysis and trends.
4. European Commission. (2021). CE Marking Regulations for Medical Devices.
5. GlobalData. (2022). Respiratory Devices Market Outlook.